SLC5A2 and hydrops fetalis: Large cardiovascular-outcome trials, including EMPA-REG OUTCOME (empagliflozin), CANVAS and CREDENCE (canagliflozin), DECLARE-TIMI 58 and DAPA-HF (dapagliflozin), and VERTIS-CV (ertugliflozin) trials, demonstrated that SGLT2 inhibitors significantly reduce hospitalizations for HF and adverse renal events, with some also showing reductions in lowering MACE [36,37].